# A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

> **NCT03401788** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 50 (estimated)

## Conditions studied

- VHL - Von Hippel-Lindau Syndrome
- VHL Gene Mutation
- VHL Syndrome
- VHL Gene Inactivation
- VHL-Associated Renal Cell Carcinoma
- VHL-Associated Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** Belzutifan

## Key facts

- **NCT ID:** NCT03401788
- **Lead sponsor:** Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-05-02
- **Primary completion:** 2027-04-29
- **Final completion:** 2027-04-29
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03401788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03401788, "A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03401788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*